Oramed Pharmaceuticals, Inc

As the primary body for 'scoring' tax legislation, its technical analysis and revenue estimates directly influence corporate tax structures and capital investment credits, which are crucial for pharmaceutical R&D and profitability.

This committee controls taxation, trade, and 'Medicare pricing,' which is a critical revenue driver for pharmaceutical companies. Its decisions on tax policy directly impact corporate profitability and R&D incentives.

This committee directly allocates federal spending, impacting funding for regulatory bodies (FDA), research (NIH), and government procurement of pharmaceuticals, directly affecting Oramed's operating environment and potential revenue streams.

This committee has direct regulatory oversight of the FDA (critical for drug approval) and NIH (influences research funding), which are existential for pharmaceutical and biotech companies like Oramed.

This committee's oversight of intellectual property (patents) and antitrust laws is foundational to the pharmaceutical industry, affecting R&D protection, market competition, and merger approvals.

Despite lacking legislative authority, its investigations and hearings on 'drug pricing' create significant headline risk and political pressure, directly impacting public perception and future policy discussions crucial for pharmaceutical companies.

This committee oversees SBA programs and R&D grants (e.g., SBIR) which are critical funding sources for smaller pharmaceutical companies, directly impacting their research, development, and growth capabilities.

The committee's funding decisions for the Department of Veterans Affairs directly impact government healthcare contractors and procurement of pharmaceuticals for veterans, potentially affecting Oramed's sales or market access.